Stay updated with breaking news from Codexis Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
28.02.2024 - Anticipate 2024 Product Revenue Growth of at Least 10% vs. 2023 Excluding Enzyme Sales Related to PAXLOVID Recently Announced Debt Financing Reinforces Strong Financial Position with Projected Runway Through Expected Positive Cash-flow Around End ...
Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings.
Shares of Helix Energy Solutions Group, Inc. (NYSE:HLX) fell sharply during Tuesday’s session following weak earnings. Helix Energy posted...
Board expertise encompasses oligonucleotide research, development, manufacturing and commercialization to support development of ECO Synthesis™...
REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Masad Damha, PhD, and Jim Lalonde, PhD,